Coherus BioSciences Inc (CHRS)

28.00
0.45 1.60
NASDAQ : Health Care
Prev Close 27.55
Open 27.60
Day Low/High 27.15 / 28.10
52 Wk Low/High 12.04 / 37.02
Volume 80.62K
Avg Volume 437.10K
Exchange NASDAQ
Shares Outstanding 43.65M
Market Cap 1.17B
EPS -6.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Coherus BioSciences Reports Third Quarter 2016 Operating And Financial Results

Coherus BioSciences Reports Third Quarter 2016 Operating And Financial Results

Continued execution on multiple fronts positions the company strongly for the remainder of 2016 and beyond

Notable Monday Option Activity: CHRS, FMI, OLED

Notable Monday Option Activity: CHRS, FMI, OLED

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Coherus BioSciences Inc , where a total of 1,527 contracts have traded so far, representing approximately 152,700 underlying shares. That amounts to about 43.6% of CHRS's average daily trading volume over the past month of 350,515 shares.

AbbVie Stock Higher on Humira Patent Win

AbbVie Stock Higher on Humira Patent Win

The Patent Trial and Appeal Board has denied Coherus's petition to make a copy of AbbVie's Humira drug.

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.

Coherus BioSciences Regains Development And Commercial Rights To CHS-0214 From Shire

Coherus BioSciences Regains Development And Commercial Rights To CHS-0214 From Shire

No Payment Due upon Return, no Obligations for Future Payments or Royalties

AbbVie's Battle Royale

AbbVie's Battle Royale

Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?

Coherus BioSciences Reports Second Quarter 2016 Financial And Operating Results

Coherus BioSciences Reports Second Quarter 2016 Financial And Operating Results

Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Coherus BioSciences Provides Update On IPRs

Coherus BioSciences Provides Update On IPRs

Patent Trial and Appeal Board Institutes Two Additional IPRs Against AbbVie's Patents

Coherus Presents Study Results Demonstrating Equivalence Of Its CHS-0214 Biosimilar To Etanercept

Coherus Presents Study Results Demonstrating Equivalence Of Its CHS-0214 Biosimilar To Etanercept

Biosimilar to etanercept meets primary endpoint

Coherus BioSciences Advances Differentiated IP Strategy For Humira Market Access

Coherus BioSciences Advances Differentiated IP Strategy For Humira Market Access

USPTO Issued Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880